Abstract | INTRODUCTION: AREAS COVERED: Clinical efficacy and safety data of etanercept for the approved indications are reviewed in this paper. Data were obtained from published clinical trials, registries, post-marketing data as well as information provided by Amgen. EXPERT OPINION:
|
Authors | Todd A Kerensky, Alice B Gottlieb, Shimrat Yaniv, Shiu-chung Au |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 11
Issue 1
Pg. 121-39
(Jan 2012)
ISSN: 1744-764X [Electronic] England |
PMID | 22074366
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- Etanercept
|
Topics |
- Anti-Inflammatory Agents, Non-Steroidal
(adverse effects, pharmacology, therapeutic use)
- Arthritis
(drug therapy, physiopathology)
- Etanercept
- Humans
- Immunoglobulin G
(adverse effects, pharmacology, therapeutic use)
- Inflammation
(drug therapy, physiopathology)
- Psoriasis
(drug therapy, physiopathology)
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|